الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 184 |  |  |
| | | from | 184 | | |
Abstract
Myocardial protection is still a focus of ongoing researches and cardioplegia is still the main appropriate way for cardiac arrest during cardiac surgery with cardiopulmonary bypass and it plays a very important role in myocardial protection strategies. Several additives have been added to the cardioplegia to enhance the myocardial protection but the ideal cardioplegia composition has not reached yet. Propofol is used widely during the induction of anesthesia in cardiac surgery. A lot of animal studies proved a cardioprotective effect of the propofol. However, its benefits when used as a cardioplegia additives are not fully studied and it is not known whether the cardioprotective effect of propofol is different depending on the route of administration either with cardioplegia or systemically. So, this triggers us to investigate the cardioprotective effect of the propofol when added to the cardioplegia compared to systemic propofol by measuring the troponin T level. Cardiac troponin T is a good indicator of the cardioprotective effect of propofol and it was used in several studies to predict the clinical outcomes.